Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection

키워드

참고문헌 (46)

1. McColl KE, "Clinical practice: Helicobacter pylori infection", N Engl J Med, 362, pp.1597~1604 (2010)
2. Malfertheiner P, "Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report", Gut, 56, pp.772~781 (2007)
3. Chey WD, "American College of Gastroenterology guideline on the management of Helicobacter pylori infection", Am J Gastroenterol, 102, pp.1808~1825 (2007)
4. Fischbach W, "S3-guideline “Helicobacter pylori and gastroduodenal ulcer disease” of the German Society for Digestive and Metabolic Diseases (DGVS) in cooperation with the German Society for Hygiene and Microbiology, Society for Pediatric Gastroenterology and Nutrition e. V., German Society for Rheumatology, AWMF-registration-no. 021", 001, 2009, pp.47, 1230~1263
5. Kim BG, "Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylori eradication: neither treatment duration provides acceptable eradication rate in Korea", Helicobacter, 12, pp.31~35 (2007)
6. 김나영, "헬리코박터 파일로리 감염의 진단 및 치료 가이드라인", 대한소화기학회지, 54(5), pp.269~278 (2009), 대한소화기학회
7. Graham DY, "Helicobacter pylori treatment in the era of increasing antibiotic resistance", Gut, 59, pp.1143~1153 (2010)
8. Gisbert JP, "Evolution of Helicobacter pylori therapy from a meta-analytical perspective", Helicobacter, 12(2), pp.50~58 (2007)
9. Della Monica P, "Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy", Aliment Pharmacol Ther, 16, pp.1269~1275 (2002)
10. O’Connor A, "Treatment of Helicobacter pylori infection 2010", Helicobacter, 15(1), pp.46~52 (2010)
11. O’Connor A, "Treatment of Helicobacter pylori infection 2011", Helicobacter, 16(1), pp.53~58 (2011)
12. Gisbert JP, "Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough", Aliment Pharmacol Ther, 34, pp.1255~1268 (2011)
13. Malfertheiner P, "Current concepts in the management of Helicobacter pylori infection: the Maastricht 2-2000 Consensus Report", Aliment Pharmacol Ther, 16, pp.167~180 (2002)
14. Hojo M, "Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection", Scand J Gastroenterol, 36, pp.690~700 (2001)
15. Gisbert JP, "Review article: Helicobacter pylori “rescue” regimen when proton pump inhibitor-based triple therapies fail", Aliment Pharmacol Ther, 16, pp.1047~1057 (2002)
16. Keating GM, "Moxifloxacin: a review of its use in the management of bacterial infections", Drugs, 64, pp.2347~2377 (2004)
17. Krasemann C, "Evaluation of the clinical microbiology profile of moxifloxacin", Clin Infect Dis, 32(1), pp.S51~S63 (2001)
18. Di Caro S, "Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication", Aliment Pharmacol Ther, 16, pp.527~532 (2002)
19. Nista EC, "Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection", Aliment Pharmacol Ther, 21, pp.1241~1247 (2005)
20. Bago P, "High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial", Wien Klin Wochenschr, 119, pp.372~378 (2007)
21. Cheon JH, "Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacterpylori infection", Helicobacter, 11, pp.46~51 (2006)
22. Bago J, "Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial", Wien Klin Wochenschr, 121, pp.47~52 (2009)
23. Li Y, "Advantages of moxifloxacin and levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis", Wien Klin Wochenschr, 122, pp.413~422 (2010)
24. Kang JM, "Second-line treatment for Helicobacter pylori infection: 10-day moxifloxacin-based triple therapy versus 2-week quadruple therapy", Helicobacter, 12, pp.623~628 (2007)
25. Cellini L, "Analysis of genetic variability, antimicrobial susceptibility and virulence markers in Helicobacter pylori identified in Central Italy", Scand J Gastroenterol, 41, pp.280~287 (2006)
26. Wang LH, "Distribution of gyrA mutations in fluoroquinolone-resistant Helicobacter pylori strains", World J Gastroenterol, 16, pp.2272~2277 (2010)
27. 정광현, "The Efficacy of Moxifloxacin-Containing Triple Therapy after Standard Triple, Sequential, or Concomitant Therapy Failure for Helicobacter pylori Eradication in Korea", Gut and Liver, 8(6), pp.605~611 (2014), 거트앤리버 발행위원회
28. 문지윤, "Levofloxacin, Metronidazole, and Lansoprazole Triple Therapy Compared to Quadruple Therapy as a Second-Line Treatment of Helicobacter pylori Infection in Korea", Gut and Liver, 7(4), pp.406~410 (2013), 거트앤리버 발행위원회
29. Lee JH, "Impact of clarithromycin resistance on eradication of Helicobacter pylori in infected adults", Antimicrob Agents Chemother, 49, pp.1600~1603 (2005)
30. 김재연, "한국인의 위·십이지장 질환에 따른 Helicobacter pylori 균주의 일차 항생제 내성과 H. pylori 제균율", 대한소화기학회지, 58(2), pp.74~81 (2011), 대한소화기학회
31. Mock T, "Clinical validation of the Helikit: a 13C urea breath test used for the diagnosis of Helicobacter pylori infection", Clin Biochem, 32, pp.59~63 (1999)
32. Megraud F, "Helicobacter pylori and antibiotic resistance", Gut, 56, pp.1502~ (2007)
33. Parente F, "Treatment options for patients with Helicobacter pylori infection resistant to one or more eradication attempts", Dig Liver Dis, 35, pp.523~528 (2003)
34. Mégraud F, "H pylori antibiotic resistance: prevalence, importance, and advances in testing", Gut, 53, pp.1374~1384 (2004)
35. Lee JW, "Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012", Helicobacter, 18, pp.206~214 (2013)
36. Mégraud F, "Review article: the treatment of refractory Helicobacter pylori infection", Aliment Pharmacol Ther, 17, pp.1333~1343 (2003)
37. Mégraud F, "Helicobacter pylori detection and antimicrobial susceptibility testing", Clin Microbiol Rev, 20, pp.280~322 (2007)
38. Lee BH, "Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea", Helicobacter, 15, pp.38~45 (2010)
39. Nishizawa T, "Quinolone-based third-line therapy for Helicobacter pylori eradication", J Clin Biochem Nutr, 44, pp.119~124 (2009)
40. Yoon H, "Moxifloxacin-containing triple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate", Helicobacter, 14, pp.77~85 (2009)
41. Miyachi H, "Primary levofloxacin resistance and gyrA", B mutations among Helicobacter pylori in Japan, 2006, pp.11, 243~249
42. Kim JM, "Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients", J Antimicrob Chemother, 56, pp.965~967 (2005)
43. Zou J, "Laboratory and clinical study of levofloxacin against Helicobacter pylori", Zhonghua Yi Xue Za Zhi, 83, pp.1778~1781 (2003)
44. Chung JW, "Resistance of Helicobacter pylori strains to antibiotics in Korea with a focus on fluoroquinolone resistance", J Gastroenterol Hepatol, 27, pp.493~497 (2012)
45. Qasim A, "Review article: treatment of Helicobacter pylori infection and factors influencing eradication", Aliment Pharmacol Ther, 16(1), pp.24~30 (2002)
46. Graham DY, "A report card to grade Helicobacter pylori therapy", Helicobacter, 12, pp.275~278 (2007)

관련 논문AI추천